<p id="hl0000052" class="ng-scope">Cardiovascular (CV) events are the most frequent cause of death for patients with chronic kidney disease (CKD), and cardiovascular mortality demonstrates a linear increase with worsening stages of renal dysfunction<span> </span><button class="j-inline-reference inline-reference" data-refid="bb0005" id="refInSitubb0005">[1]</button><span> </span>.</p> <p id="hl0000054" class="ng-scope">Coronary artery disease (CAD) is one of the primary drivers for the increased CV risk, and its management is affected by the presence of CKD. The application of therapeutic modalities proven beneficial in other cohorts is limited for patients with CKD given the paucity of robust scientific data that specifically includes this patient population. In addition, patients with CKD frequently have a multitude of comorbidities that make them prone to procedural complications and poor clinical outcomes<span> </span><button class="j-inline-reference inline-reference" data-refid="bb0010" id="refInSitubb0010">[2]</button><span> </span>.</p>